Cargando…

The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients

BACKGROUND: Few data are available on the clinical features and outcomes of Chinese patients with systemic immunoglobulin light-chain (AL) amyloidosis. The aim of this study is to reveal the clinical picture and risk factors of disease progression in a large cohort of Chinese patients with AL amyloi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xianghua, Wang, Qingwen, Jiang, Song, Chen, Wencui, Zeng, Caihong, Liu, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310422/
https://www.ncbi.nlm.nih.gov/pubmed/25713722
http://dx.doi.org/10.1093/ckj/sfu117
_version_ 1782354872479252480
author Huang, Xianghua
Wang, Qingwen
Jiang, Song
Chen, Wencui
Zeng, Caihong
Liu, Zhihong
author_facet Huang, Xianghua
Wang, Qingwen
Jiang, Song
Chen, Wencui
Zeng, Caihong
Liu, Zhihong
author_sort Huang, Xianghua
collection PubMed
description BACKGROUND: Few data are available on the clinical features and outcomes of Chinese patients with systemic immunoglobulin light-chain (AL) amyloidosis. The aim of this study is to reveal the clinical picture and risk factors of disease progression in a large cohort of Chinese patients with AL amyloidosis. METHODS: Patients in the Jinling Hospital amyloidosis registry from 2003 to 2011 were studied. The clinical and laboratory information were collected from first presentation to death or until the last available clinical follow-up. The patients' survival and renal outcomes were analyzed, and the relationships between the clinical parameters and survival were also assessed. RESULTS: A total of 231 patients were enrolled in this study, all the patients studied had renal involvement. One hundred and fifty-three (66.2%) were male, and the median age at diagnosis was 56 years. A total of 198 (85.7%) cases had light-chain λ-type. One hundred and forty-seven (63.6%) cases presented as nephrotic syndrome (NS), and 25% of patients had renal insufficiency at diagnosis. Liver involvement and NS appeared to be more common in patients of κ-type amyloidosis, and renal impairment is more severe in κ-type amyloidosis. The median survival time of all patients was 36.3 months, and the 1-, 2-, 3- and 5-year cumulative survival rates were 67, 53, 48 and 35%, respectively. Multivariate COX analysis showed that age, hepatic involvement and heart involvement can significantly influence survival in these patients. The median time that patients remained dialysis free was 50 months. The percentage of patients that remained dialysis free at 1, 2, 3 and 5 years were 78, 69, 62 and 37%, respectively. Multivariate COX analysis showed that serum creatinine and hypotension were the important risk factors of renal failure. CONCLUSION: λ-Type is the most dominant type of AL amyloidosis in Chinese patients. The survival of patients with AL amyloidosis is poor. The risk factors included heart and hepatic involvement, hypotension and impairment of renal function. The high serum creatinine level and hypotension at diagnosis are associated with poor renal outcome.
format Online
Article
Text
id pubmed-4310422
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43104222015-02-24 The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients Huang, Xianghua Wang, Qingwen Jiang, Song Chen, Wencui Zeng, Caihong Liu, Zhihong Clin Kidney J Contents BACKGROUND: Few data are available on the clinical features and outcomes of Chinese patients with systemic immunoglobulin light-chain (AL) amyloidosis. The aim of this study is to reveal the clinical picture and risk factors of disease progression in a large cohort of Chinese patients with AL amyloidosis. METHODS: Patients in the Jinling Hospital amyloidosis registry from 2003 to 2011 were studied. The clinical and laboratory information were collected from first presentation to death or until the last available clinical follow-up. The patients' survival and renal outcomes were analyzed, and the relationships between the clinical parameters and survival were also assessed. RESULTS: A total of 231 patients were enrolled in this study, all the patients studied had renal involvement. One hundred and fifty-three (66.2%) were male, and the median age at diagnosis was 56 years. A total of 198 (85.7%) cases had light-chain λ-type. One hundred and forty-seven (63.6%) cases presented as nephrotic syndrome (NS), and 25% of patients had renal insufficiency at diagnosis. Liver involvement and NS appeared to be more common in patients of κ-type amyloidosis, and renal impairment is more severe in κ-type amyloidosis. The median survival time of all patients was 36.3 months, and the 1-, 2-, 3- and 5-year cumulative survival rates were 67, 53, 48 and 35%, respectively. Multivariate COX analysis showed that age, hepatic involvement and heart involvement can significantly influence survival in these patients. The median time that patients remained dialysis free was 50 months. The percentage of patients that remained dialysis free at 1, 2, 3 and 5 years were 78, 69, 62 and 37%, respectively. Multivariate COX analysis showed that serum creatinine and hypotension were the important risk factors of renal failure. CONCLUSION: λ-Type is the most dominant type of AL amyloidosis in Chinese patients. The survival of patients with AL amyloidosis is poor. The risk factors included heart and hepatic involvement, hypotension and impairment of renal function. The high serum creatinine level and hypotension at diagnosis are associated with poor renal outcome. Oxford University Press 2015-02 2014-11-13 /pmc/articles/PMC4310422/ /pubmed/25713722 http://dx.doi.org/10.1093/ckj/sfu117 Text en © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Contents
Huang, Xianghua
Wang, Qingwen
Jiang, Song
Chen, Wencui
Zeng, Caihong
Liu, Zhihong
The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
title The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
title_full The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
title_fullStr The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
title_full_unstemmed The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
title_short The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
title_sort clinical features and outcomes of systemic al amyloidosis: a cohort of 231 chinese patients
topic Contents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310422/
https://www.ncbi.nlm.nih.gov/pubmed/25713722
http://dx.doi.org/10.1093/ckj/sfu117
work_keys_str_mv AT huangxianghua theclinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT wangqingwen theclinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT jiangsong theclinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT chenwencui theclinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT zengcaihong theclinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT liuzhihong theclinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT huangxianghua clinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT wangqingwen clinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT jiangsong clinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT chenwencui clinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT zengcaihong clinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients
AT liuzhihong clinicalfeaturesandoutcomesofsystemicalamyloidosisacohortof231chinesepatients